Evidence map›Paper›PMID 39076091›Full record

ReviewAnti-inflammatory & anti-allergy agents in medicinal chemistry2025

Naringenin: A Promising Immunomodulator for Anti-inflammatory, Neuroprotective and Anti-cancer Applications.

Sarita Solanki, Himangi Vig, Nidhi Khatri, Bhanu Pratap Singh, Mohammad Shahid Khan, Manish Devgun, Pranay Wal, Ankita Wal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sarita SolankiDepartment of Pharmacy, University of Kota, Kota Rajasthan, India.
Himangi VigPSIT-Pranveer Singh Institute of Technology (Pharmacy), NH 19 Bhauti Kanpur, Uttar Pradesh, India.
Nidhi KhatriDepartment of Pharmacy, University of Kota, Kota Rajasthan, India.
Bhanu Pratap SinghDepartment of Pharmacy, University of Kota, Kota Rajasthan, India.
Mohammad Shahid KhanMaharshi Arvind institute of pharmacy, Ranpur, Kota, India.
Manish DevgunInstitute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, Haryana, India.
Pranay WalPSIT-Pranveer Singh Institute of Technology (Pharmacy), NH 19 Bhauti Kanpur, Uttar Pradesh, India.ORCID 0000-0002-6342-6290
Ankita WalPSIT-Pranveer Singh Institute of Technology (Pharmacy), NH 19 Bhauti Kanpur, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory, immune, and neurodegenerative diseases constitute a category of persistent and debilitating conditions affecting millions worldwide, with intertwined pathophysiological pathways. Recent research has spotlighted naturally occurring compounds like naringenin for potential therapeutic applications across multiple ailments.

objectivesThis review offers an encompassing exploration of naringenin's anti-inflammatory, immune-protective, and neuroprotective mechanisms, elucidating its pharmacological targets, signal transduction pathways, safety profile, and insights from clinical investigations.

methodsData for this review were amassed through the scrutiny of various published studies

resultsNaringenin exhibits substantial anti-inflammatory effects by restraining the NF-κB signaling pathway. It activates Nrf2, renowned for its anti-inflammatory properties, inducing the release of hemeoxynase-1 by macrophages. Furthermore, naringenin treatment downregulates the expression of Th1 cytokines and inflammatory mediators. It also impedes xanthine oxidase, counteracts reactive oxygen species (ROS), scavenges superoxide radicals, mitigates the accessibility of oxygen-induced K+ erythrocytes, and reduces lipid peroxidation. Naringenin's antioxidant prowess holds promise for addressing neurological conditions.

conclusionExtensive research has been undertaken to establish the anti-inflammatory, immunomodulatory, and neuroprotective attributes of naringenin across various medical domains, lending credence to its pharmacological utility. The principal obstacle to naringenin's adoption as a therapeutic agent remains the dearth of in vivo data. Efforts should focus on rendering naringenin delivery patient-friendly, economically viable, and technologically advanced.

Indexed as

Anti-Inflammatory AgentsAntineoplastic AgentsFlavanonesImmunologic FactorsImmunomodulating AgentsNeuroprotective AgentsAnimalsHumansSignal TransductionAnti-Inflammatory AgentsAntineoplastic AgentsFlavanonesImmunologic FactorsImmunomodulating AgentsnaringeninNeuroprotective Agentsalzheimer's diseaseanti-canceranti-inflammatorydiabetes mellitesimmunomodulatorNaringeninneuroprotectiveparkinson’s disease.

Identifiers

PMID39076091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.